Sleep Regularity and Mortality: A Prospective Analysis in the UK Biobank Lachlan Cribb* (MEpi), Ramon Sha* (BSc), Stephanie Yiallourou* (Ph.D.), Natalie A Grima (DPsyc), Marina Cavuoto (Ph.D.)^{1,2}, Andree-Ann Baril¹ (Ph.D.)³, Matthew P. Pase¹ (Ph.D.)^{1,4} ¹Turner Institute for Brain and Mental Health, Monash University, Melbourne Australia; ²National Ageing Research Institute, Melbourne, Australia; ³Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada; ⁴Harvard T.H. Chan School of Public Health, Harvard University, MA, USA. *Joint first authors Correspondence to: Matthew Pase, 18 Innovation Walk, Room 617, Monash University, Clayton, VIC, Australia, 3800. Phone: (+61)401267924. email - matthewpase@gmail.com. Word Count: 2716

ABSTRACT Background Irregular sleep-wake timing may cause circadian disruption leading to several chronic age-related diseases. We examined the relationship between sleep regularity and risk of all-cause, cardiovascular disease (CVD), and cancer mortality in 88,975 participants from the prospective UK Biobank cohort. Methods The sleep regularity index (SRI) was calculated as the probability of an individual being in the same state (asleep or awake) at any two time points 24 hours apart, averaged over 7-days of accelerometry (range 0-100, with 100 being perfectly regular). The SRI was related to the risk of mortality in time-to-event models. Findings The mean sample age was 62 years (SD, 8), 56% were women, and the median SRI was 60 (SD, 10). There were 3010 deaths during a mean follow-up of 7.1 years. Following adjustments for demographic and clinical variables, we identified a non-linear relationship between the SRI and all-cause mortality hazard (p [global test of spline term] < 0.001). Hazard Ratios, relative to the median SRI, were 1.53 (95% confidence interval [CI]: 1.41, 1.66) for participants with SRI at the 5th percentile (SRI = 41) and 0.90 (95% CI: 0.81, 1.00) for those with SRI at the 95th percentile (SRI = 75), respectively. Findings for CVD mortality and cancer mortality followed a similar pattern. **Conclusions** Irregular sleep-wake patterns are associated with higher mortality risk. Funding National Health and Medical Research Council of Australia (GTN2009264; GTN1158384), National Institute on Aging (AG062531), Alzheimer's Association (2018-AARG-591358), and the Banting Fellowship Program (#454104).

81

82

83

84

85

8687

88

89

90

91

92

93

94

95 96

97

98

99

100

101

102

103

104105

106

107

108109

110

111112

113

114

115

116

117

118

119

comparable.

2

INTRODUCTION Circadian rhythms are endogenous cycles in physiological, hormonal, and behavioral processes largely synchronized to the external 24-hour light-dark cycle. The sleep-wake cycle is perhaps the most notable biological process that follows the 24-hour circadian rhythm. The timing of light exposure is the primary external driver of circadian rhythms. Therefore, rapid changes in sleep timing can cause circadian misalignment through fluctuating light-dark exposure.² Circadian misalignment is associated with several age-related diseases, including cancer and cardiovascular disease (CVD).³⁻⁵ However, the health impacts of irregular sleep wake timing are still emerging. This remains an important area of study since modern societal and lifestyle trends, including exposure to artificial and blue light at night, longer work hours, shift work, and the 24-7 lifestyle have blurred the distinction between day and night, increasing the propensity for circadian disruption. The present study assessed the relationship between sleep regularity and the risk of incident all-cause mortality, cancer mortality, and CVD mortality in the UK Biobank (UKB). We measured sleep regularity via accelerometry to calculate the sleep regularity index (SRI), a new metric sensitive to differences in sleep-wake timing on a circadian timescale. **METHODS Participants** Over 500,000 adults aged 40 to 69 years were recruited to the UKB cohort between 2006 and 2010 across 22 assessment centers. Participants were invited by the UK National Health Service patient registers, resulting in a 5.5% participation rate. Respondents were more likely to be older, female, and less likely to live in socioeconomically deprived areas than the general population. Baseline demographics, medical history, lifestyle, vitals, and blood samples were collected. A total of 106,053 participants completed a 7-day wrist-worn accelerometer study through random selection between February 2013 and December 2015. Measurement of sleep regularity Accelerometry data were collected using a wrist-worn device (Axivity AX3, United Kingdom) over a 7day/night period. Estimated sleep status (awake or asleep) at a given time was calculated using the open-source R package GGIR version 2·7-1,8 using available algorithms.9,10 Accelerometry data of low quality were removed using established UKB criteria (Appendix 1, pg. 3). In total, 88,975 (84%) participants provided valid SRI data and were included in the study. The SRI captures the probability of a participant being in the same state (asleep or awake) at any two time points 24 hours apart. 11 An individual who sleeps and wakes at precisely the same time each day would have an index of 100, whereas an individual who sleeps and wakes at entirely random times would have an index of 0. Each participant provided k-1 SRI measurements (where k is the number of valid 24-hour periods), one for each contiguous two-day pair. These SRI measurements were averaged using a linear mixed effects model with a random intercept for the participant and fixed effects for the day of the week and daylight savings transition. The average SRI was standardized over the day of the week and daylight savings transitions, so all SRI results were

122

123

124

125

126127

128

129

130

131

132

133134

135

136

137

138

139

140

141

142

143

144145

146147

148

149

150

151

152

153

154155

156

157

158

3

Mortality ascertainment Mortality occurrence was identified through linkage with NHS Digital for participants from England and Wales and the NHS Central Register for participants from Scotland, with complete records available until January 2022. Death records included the date of death and the ICD-10 code for the primary cause. ICD-10 codes I00-199 and C00-C97 defined CVD and cancer mortality, respectively. Ascertainment of prevalent disease at baseline Prevalent cancer (ICD-10 codes D00-D09 and D37-D48), diabetes (codes E10-E14), mental and behavioral disorders (codes F00-F99), nervous system disorders (codes G00-G99), and CVD (codes I00-I99) at the time of the accelerometry study were ascertained through self-report at the UKB baseline session and through linkage with hospital inpatient records using the above ICD-10 codes. Linkage with hospital inpatient records was also used to identify disease occurrence between the UKB baseline session and the time of the accelerometry study. Data Analysis Data analysis was performed using R version $4 \cdot 2 \cdot 1$. Cox proportional hazards models were used to examine associations between the SRI and incident all-cause mortality, CVD mortality, and cancer mortality. Surveillance for mortality commenced from the time of accelerometry (2013-2015) until the end of follow-up (January 2022), with a median follow-up time of 7.1 years (Q1, Q3: 6.6, 7.6). Non-events were censored at the last date they were known to be alive. For CVD and cancer mortality, deaths from competing causes were censored at the time of death. The SRI and all continuous confounders were modeled with restricted cubic splines with knots at the 10th, 50th, and 90th percentiles to allow for departures from linearity. Missing data were infrequent (< 2%) for most confounder variables and were imputed (10 imputations) by predictive mean matching using the aregImpute function of R package *Hmisc.*¹² In addition to Cox models, discrete-time hazards models, including an interaction between SRI and time (aggregated into 3-month intervals and modeled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles), were fitted to determine whether Hazard Ratios (HRs) varied over time. ¹³ Time-varying HRs were then displayed visually. In cases where HRs showed clear time-variation (i.e., hazards were nonproportional), we nonetheless present HRs from the Cox models as these can be interpreted as a weighted average of the time-varying HRs. 14 The discrete-time hazards model for all-cause mortality was also used to estimate standardized cumulative incidence (risk) across levels of SRI, with confidence intervals obtained by bootstrapping. 15 To reduce computation demand, only single imputation was used for the discrete-time hazards models. All models were adjusted for the following variables that were selected using a directed acyclic graph (Appendix, Figure S1): age, sex, ethnicity (White, Asian, mixed race, Black, or other), Townsend deprivation index, retirement status (retired vs. all other work arrangements), shift work (shift worker vs. non-shift worker), sick or disabled (self-reported employment category), household income (ordinal with 5 levels), highest level of

education (ordinal with 6 levels), smoking status (current, former, never), smoking (pack years), and use of sedative, antidepressant, or antipsychotic medication.

Sensitivity analyses

We fitted a second statistical model to determine whether the observed associations were independent of sleep time and disruption. Therefore, Model 2 included additional adjustments for overnight sleep duration and wake after sleep onset (WASO), averaged across accelerometry days (plus primary model covariates). In the second sensitivity analysis (Model 3), we adjusted for prevalent disease at baseline (cancer, CVD, mental and behavioural disorders, nervous system disorders, diabetes), in addition to the variables in the primary model. These variables were included as part of a sensitivity analysis as it is unclear whether they may be mediators or confounders of the SRI-mortality relationship. Long-standing irregular sleep may lead to prevalent disease at baseline and influence disease risk factors, ¹⁶⁻¹⁹ indicating that prevalent disease variables may play a mediating role (and consequently should not be adjusted). Conversely, prevalent disease may have effects disruptive to regular sleep and these variables may therefore confound the SRI-mortality relationship. Disease risk factor variables body mass index (BMI), moderate and vigorous physical activity (accelerometry-derived), systolic blood pressure (BP), and use of BP lowering medication, in addition to the variables in Model 3, were included in a final sensitivity analysis (Model 4), as it is similarly unclear whether they may confound or mediate the SRI-mortality relationship.

Comparison of SRI with other regularity measures

Preliminary reports which identified irregular sleep as a potential CVD risk factor measured sleep regularity as the amount of deviation in sleep patterns from an individual's average (i.e., the standard deviation [SD] of nocturnal sleep duration and sleep onset time). To contrast these SD-based metrics with the SRI, we fitted independent Cox models (each with primary model covariates) and estimated HRs for all-cause mortality for each of the three measures. Additionally, we added the SRI to a model containing both SD-based regularity measures (alongside primary model covariates) to test whether the SRI contained additional mortality risk information beyond that captured by the two SD metrics.

188 RESULTS

Table 1 displays sample characteristics. The final sample size was 88,975. There were 3010 all cause deaths during a median follow-up of $7 \cdot 1$ years (Q1, Q3: $6 \cdot 6$, $7 \cdot 6$). The most common primary cause of death was cancer (n = 1701, 57%) followed by CVD (n = 616, 20%).

SRI and all-cause mortality

We identified a non-linear association between the SRI and all-cause mortality hazard (p [global test of spline term] < 0·001) (**Figure 1**). Compared to the sample median (SRI = 61), mortality rates were highest among those with the most irregular sleep and decreased almost linearly as SRI approached its median, after which the decrease began to plateau (**Figure 1**). HRs, relative to the median SRI, were 1·53 (95% CI: 1·41, 1·66) for participants with SRI at the 5^{th} percentile (SRI = 41) and 0.90 (95% CI: 0·81, 1·00) for those with SRI at the 95^{th}

200

201202

203

204

205

206

207

208209

210

211

212

213

214215

216

217

218

219

220

221

222

223224

225

226

227

228

229

230

231232

233

234

235

236

237

5

percentile (SRI = 75), respectively. Standardized cumulative incidence curves for all-cause mortality are displayed for the SRI at the 5th percentile, median, and 95th percentile in **Figure 2**. There was evidence of non-proportionality of hazards across levels of SRI in the discrete-time hazards model (p [time x SRI interaction] < 0.001). Time-varying HRs for the 5th and 95th SRI percentiles compared to the median are displayed in the appendix (Figure S2). For the 5th percentile relative to the median, HRs were greatest in the earliest period of follow-up (HRs> 2), declining until approximately 2.5 years, after which they remained approximately stable with a HR of around 1.5. There was no clear time variation in the HR for the 95th percentile of SRI vs. the median. CVD-specific mortality The SRI was associated with CVD-specific mortality in the primary model (p [global] < 0.001; Figure 1). HRs, relative to the median SRI, were 1.88 (95% CI: 1.61, 2.21) and 0.93 (95% CI: 0.73, 1.20) for the 5th and 95th percentiles, respectively. There was no evidence of non-proportional hazards in the discrete-time hazards model (p [time x SRI interaction] = 0.57). Cancer-specific mortality The SRI was associated with cancer mortality in the primary model (p [global] < 0.001). HRs, relative to the median SRI, were 1.36 (95% CI: 1.22, 1.53) and 0.89 (95% CI: 0.77, 1.02) for the 5th and 95th percentiles, respectively. There was strong evidence of non-proportional hazards in the cancer-mortality discrete-time hazards model (p [time x SRI interaction] < 0.001). HRs. for the 5th percentile vs. the median, were large at the beginning of follow-up (HRs> 2) and declined until approximately four years, after which they were small (~ 1.05) and compatible with the null (Appendix, Figure S3). There was no indication that HRs for the 95th SRI percentile relative to the median varied over follow-up. Sensitivity analyses Sensitivity analyses are displayed in the appendix (Figures S4-6). Overall, results were similar and not meaningfully altered following adjustments for sleep time and WASO (Model 2) or prevalent baseline disease, including cancer and CVD (Model 3). The SRI remained associated with mortality after further adjustments for prevalent diseases, BMI, systolic BP, BP treatment, and physical activity (Model 4), though effect sizes were attenuated. For example, when comparing the 5th percentile to the median, HRs were 1·22 (95% CI: 1·07, 1·39) for all-cause, 1.43 (95% CI: 1.21, 1.69) for CVD, and 1.15 (95% CI: 1.01, 1.29) for cancer mortality. Comparison of SRI with sleep duration SD and sleep onset time SD Figure 3 displays HRs, relative to the median, for the SRI, sleep duration SD, and sleep onset time SD. For each measure, greater sleep irregularity (i.e., lower SRI or higher SD representing more day-to-day variability) was associated with an increased all-cause mortality rate in independent models (all p [global] < 0.001). HRs, for low regularity compared to the median, were largest for the SRI (Figure 3). The addition of the SRI to a model containing both SD metrics (alongside primary model covariates) improved model fit (p [likelihood ratio test] <

239

240241242

243

244

245

246

247

248

249250

251

252

253

254

255

256

257

258

259

260261

262

263

264265

266

267

268

269

270271

272

273

274

275

276

277

6

0.001). Conversely, the addition of sleep duration SD and sleep onset time SD to a model containing the SRI (and primary model covariates) did not meaningfully improve model fit (p [likelihood ratio test] = 0.10). DISCUSSION Among 88,975 individuals followed for a median of 7·1 years, there was a non-linear association between sleep regularity and the risk of mortality; mortality rates were highest in persons with the most irregular sleep and decreased approximately linearly as sleep regularity approached its median, after which the decrease began to plateau. Our findings were independent of prevalent illness (including cancer and CVD at baseline), sleep duration, sleep fragmentation, and other confounding factors. Overall, these data indicate a relationship between sleep regularity and longevity in a large community-based cohort. Physiological processes associated with CVD and cancer are under circadian control. Mutations or deletions to circadian clock genes such as CLOCK, PER, and BMAL1 influence BP, endothelial function, and glucose homeostasis. ²²⁻²⁵ Both major (e.g., chronic shift work) and minor (e.g., daylight savings transitions) stressors to the circadian system have been associated with a higher risk of CVD. 3.5 Similarly, circadian misalignment has also been implicated in the pathogenesis of cancer. For example, circadian clocks are critical to the orchestration of cell division²⁶, and altered clock function can precipitate aberrant cell proliferation²⁷ as well as growth and DNA damage in cancer cells.²⁸ Many systems are under circadian influence, including the sleep-wake cycle, and less clear has been the extent to which differences in sleep regularity are related to negative health outcomes. We extend this research by demonstrating that differences in sleep regularity are associated with the risk of mortality from both CVD and cancer. Whereas sleep regularity has not been examined with respect to incident cancer or mortality, the current findings extend research showing that greater sleep-wake variability, as measured by the SD of sleep onset or duration, was independently associated with a higher risk of incident CVD in the multi-ethnic study of atherosclerosis but not the UK Biobank. 20,21 We demonstrate that the SRI contains information about mortality risk beyond that contained in the SD of sleep duration and onset, whereas the converse was not the case. The SRI may be superior to the SD-based metrics because the SRI captures rapid changes in sleep patterns across consecutive days, as compared to the SD-based metrics which only calculate deviation from an individual's average. Rapid changes in sleep timing have been hypothesised as being principally challenging for the circadian system to accommodate¹¹ which may, in turn, produce negative health outcomes. We found evidence that hazard rates across levels of SRI were non-proportional (i.e., varied across the followup period) for all-cause and cancer mortality (which accounted for most deaths), though not for CVD mortality. For cancer mortality, HRs for low SRI compared to the median were largest in the earliest follow-up period and decreased thereafter. One plausible interpretation of this finding is that irregular sleep may be a manifestation of the underlying physiological processes of cancer itself or of cancer treatment (i.e., the SRI-cancer mortality

association may be due to reverse causation). However, this thesis is challenged by the fact that associations

between the SRI and cancer mortality remained similar after adjusting for prevalent cancer at baseline. In the

279

280281

282

283

284

285

286

287

288289

290

291

292

293

294

295

296

297

298299

300

301

302

303

304305

306

307

308

309

310

311312313

314

315316

317

7

case of CVD mortality, no such evidence of a decline in HRs over follow-up time was evident; a potential causal role of irregular sleep on CVD death cannot be easily ruled out. Sleep of insufficient or excessive duration is associated with many adverse health outcomes, including increased mortality risk.²⁹ As of 2022, sleep duration was included by the American Heart Association in their Essential Eight guidelines for CVD prevention.³⁰ However, sleep is far more complex than its habitual duration and quality, with sleep regularity receiving comparatively little attention. As sleep-tracking wearables become more accessible, objective measurement of sleep regularity has the potential for public and clinical use. Much like sleep duration, replicating the current findings across different samples will be necessary for establishing population norms and clinical targets. Our study is not without limitations. Firstly, the study was observational. We are, therefore, unable to establish cause and effect. Although we performed extensive analyses to control for confounding, we cannot exclude the possibility that our results are explained by residual confounding. As such, although therapies exist for improving sleep regularity, it's not clear if these interventions are able to extend the lifespan. Second, sleep and wake were estimated through activity patterns from accelerometry. As compared to polysomnography, there is the potential to misclassify sleep and wake, although accelerometry is more suited to estimate circadian patterns over several days; there are several strengths to using accelerometry (e.g., days of continuous recording, minimal technical apparatus affecting sleep quality), making it the recommended clinical tool for assessing circadian rhythms.31 Circadian rhythms have a major influence on health and disease. Although sleep wake timing is under circadian control, research on sleep regularity as a risk factor for mortality was equivocal. These data suggest sleep regularity as an important correlate of longevity, independent of sleep duration, fragmentation, and quality. Future work is needed to determine the underlying mechanisms to inform possible interventions to extend the lifespan. **FUNDING** Dr. Pase is supported by a National Health and Medical Research Council of Australia Investigator Grant (GTN2009264) with sleep research funding from the National Health and Medical Research Council of Australia (GTN1158384), National Institute on Aging (R01 AG062531) and Alzheimer's Association (2018-AARG-591358). Dr. Baril is funded by the Banting Fellowship Program (#454104). The funders of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. **ACKNOWLEDGMENTS** This research has been conducted using the UK Biobank Resource. DATA SHARING

Data from the UK Biobank are available, pending application approval from: https://www.ukbiobank.ac.uk/

318 REFERENCES

- 319 1. Zee PC, Vitiello MV. Circadian Rhythm Sleep Disorder: Irregular Sleep Wake
- 320 Rhythm Type. *Sleep Med Clin* 2009; **4**(2): 213-8.
- 321 2. Zeitzer JM, Dijk DJ, Kronauer R, Brown E, Czeisler C. Sensitivity of the human
- 322 circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol
- 323 2000; **526 Pt 3**(Pt 3): 695-702.
- 324 3. Torquati L, Mielke GI, Brown WJ, Kolbe-Alexander T. Shift work and the risk of
- 325 cardiovascular disease. A systematic review and meta-analysis including dose-response
- relationship. Scand J Work Environ Health 2018; 44(3): 229-38.
- 327 4. International-Agency-for-Research-on-Cancer. Painting, firefighting, and shiftwork.
- 328 IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2010; **98**: 804.
- 329 5. Janszky I, Ljung R. Shifts to and from Daylight Saving Time and Incidence of
- 330 Myocardial Infarction. New England Journal of Medicine 2008; **359**(18): 1966-8.
- 331 6. Walker WH, Walton JC, DeVries AC, Nelson RJ. Circadian rhythm disruption and
- mental health. Translational Psychiatry 2020; 10(1): 28.
- 7. Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-
- Related Characteristics of UK Biobank Participants With Those of the General Population.
- 335 *Am J Epidemiol* 2017; **186**(9): 1026-34.
- 336 8. Migueles JH, Rowlands AV, Huber F, Sabia S, van Hees VT. GGIR: a research
- community-driven open source R package for generating physical activity and sleep
- outcomes from multi-day raw accelerometer data. Journal for the Measurement of Physical
- 339 *Behaviour* 2019; **2**(3): 188-96.
- 340 9. Van Hees VT, Sabia S, Anderson KN, et al. A novel, open access method to assess
- sleep duration using a wrist-worn accelerometer. *PloS one* 2015; **10**(11): e0142533.
- 342 10. van Hees VT, Sabia S, Jones SE, et al. Estimating sleep parameters using an
- accelerometer without sleep diary. Scientific reports 2018; **8**(1): 1-11.
- 344 11. Phillips AJ, Clerx WM, O'Brien CS, et al. Irregular sleep/wake patterns are associated
- with poorer academic performance and delayed circadian and sleep/wake timing. *Scientific*
- 346 reports 2017; **7**(1): 1-13.
- 347 12. Harrell Jr FE, Harrell Jr MFE. Package 'hmisc'. CRAN2018 2019; 2019: 235-6.
- 348 13. Singer JD, Willett JB. Applied Longitudinal Data Analysis: Modeling Change and
- Event Occurrence: Oxford University Press; 2003.
- 350 14. Stensrud MJ, Hernán MA. Why Test for Proportional Hazards? JAMA 2020; 323(14):
- 351 1401-2.
- 352 15. Hernán MA, Robins JM. Causal inference. CRC Boca Raton, FL; 2010.
- 353 16. Fritz J, Phillips AJK, Hunt L, et al. Cross-sectional and prospective associations
- between sleep regularity and metabolic health in the Hispanic community Health Study/Study
- 355 of Latinos. *Sleep* 2021; **44**(4): zsaa218.
- Huang T, Redline S. Cross-sectional and prospective associations of actigraphy-
- assessed sleep regularity with metabolic abnormalities: the multi-ethnic study of
- 358 atherosclerosis. *Diabetes care* 2019; **42**(8): 1422-9.
- 359 18. Huang W-C, Chang S-H, Hsueh M-C, Liao Y. Relationship of sleep regularity with
- device-based sedentary behavior time and physical activity time in working adults. Sleep
- 361 Health 2022.
- 362 19. Zuraikat FM, Makarem N, Redline S, Aggarwal B, Jelic S, St-Onge M-P. Sleep
- 363 regularity and cardiometabolic heath: is variability in sleep patterns a risk factor for excess
- adiposity and glycemic dysregulation? Current diabetes reports 2020; 20(8): 1-9.
- 365 20. Nikbakhtian S, Reed AB, Obika BD, et al. Accelerometer-derived sleep onset timing
- and cardiovascular disease incidence: a UK Biobank cohort study. European Heart Journal -
- 367 *Digital Health* 2021; **2**(4): 658-66.

- The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol* 2020; **75**(9): 991-9.
- 370 22. Viswambharan H, Carvas JM, Antic V, et al. Mutation of the Circadian Clock Gene
- 371 <i>Per2</i> Alters Vascular Endothelial Function. *Circulation* 2007; **115**(16): 2188-95.
- 23. Curtis AM, Cheng Y, Kapoor S, Reilly D, Price TS, Fitzgerald GA. Circadian
- variation of blood pressure and the vascular response to asynchronous stress. *Proc Natl Acad*
- 374 *Sci U S A* 2007; **104**(9): 3450-5.
- 375 24. Anea CB, Zhang M, Stepp DW, et al. Vascular disease in mice with a dysfunctional
- 376 circadian clock. *Circulation* 2009; **119**(11): 1510-7.
- 377 25. Rudic RD, McNamara P, Curtis AM, et al. BMAL1 and CLOCK, two essential
- 378 components of the circadian clock, are involved in glucose homeostasis. *PLoS Biol* 2004;
- 379 **2**(11): e377.
- 380 26. Reddy AB, Wong GK, O'Neill J, Maywood ES, Hastings MH. Circadian clocks:
- neural and peripheral pacemakers that impact upon the cell division cycle. *Mutat Res* 2005;
- **574**(1-2): 76-91.
- Wang Q, Ao Y, Yang K, Tang H, Chen D. Circadian clock gene Per2 plays an
- important role in cell proliferation, apoptosis and cell cycle progression in human oral
- 385 squamous cell carcinoma. *Oncol Rep* 2016; **35**(6): 3387-94.
- 386 28. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per l
- plays an important role in cell growth and DNA damage control in human cancer cells. *Mol*
- 388 *Cell* 2006; **22**(3): 375-82.
- 389 29. Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Sleep duration and all-cause
- mortality: a systematic review and meta-analysis of prospective studies. *Sleep* 2010; **33**(5):
- 391 585-92.
- 392 30. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and
- 393 Enhancing the American Heart Association's Construct of Cardiovascular Health: A
- Presidential Advisory From the American Heart Association. Circulation 2022; 146(5): e18-
- 395 e43.

- 396 31. Smith MT, McCrae CS, Cheung J, et al. Use of Actigraphy for the Evaluation of Sleep
- 397 Disorders and Circadian Rhythm Sleep-Wake Disorders: An American Academy of Sleep
- 398 Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J Clin Sleep Med
- 399 2018; **14**(7): 1209-30.

Variable Summary Sex (male), n (%) 38,868 (44) Age (years) 61,9 (7.8) BMI 26.7 (4.5) Ethnicity, n (%) *** Asian 3,423 (4) Black 342 (0.4) Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) ** <18 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 27,893 (31) Shift worker, n (%) 27,893 (31) Smoking status, n (%) ** Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1) Antidepressant medication, n (%) 50,718 (6) <td< th=""><th colspan="3">Table 1: Sample characteristics (n = 88,975)</th></td<>	Table 1 : Sample characteristics (n = 88,975)		
Age (years) 61.9 (7.8) BMI 26.7 (4.5) Ethnicity, n (%)	Variable	Summary	
Age (years) 61.9 (7.8) BMI 26.7 (4.5) Ethnicity, n (%) Asian 3,423 (4) Black 342 (0.4) Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 3,927 (4) Smoking status, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1) Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)			
BMII 26.7 (4.5) Ethnicity, n (%)	Sex (male), n (%)	38,868 (44)	
Ethnicity, n (%) 3,423 (4) Asian 3,423 (0.4) Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 5,786 (7) Retired, n (%) 5,786 (7) Retired, n (%) 3,927 (4) Smoking status, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	= -	` /	
Asian 3,423 (4) Black 342 (0.4) Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) <18 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1) Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)	BMI	26.7 (4.5)	
Black 342 (0.4) Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 3,927 (4) Smoking status, n (%) 50,718 (57) Sedative medication, n (%) 781 (<1)	Ethnicity, n (%)		
Mixed race 2,513 (3) White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Asian	3,423 (4)	
White 81,902 (92) Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 418 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Black	342 (0.4)	
Other 507 (1) Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 418 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) > 100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 40,104 (7) Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1) Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)	Mixed race	2,513 (3)	
Townsend deprivation index (score units), median (Q1-Q3) -2.44 (-3.81, -0.17) Household income* (thousands), n (%) 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	White	81,902 (92)	
Household income* (thousands), n (%) <18 11,784 (15) 18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) Smoking status, n (%) Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) Antidepressant medication, n (%) Prevalent cancer, n (%) 11,638 (13)	Other	507 (1)	
<18	Townsend deprivation index (score units), median (Q1-Q3)	-2.44 (-3.81, -0.17)	
18-30 19,340 (24) 31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) Current Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Household income* (thousands), n (%)		
31-50 22,936 (29) 51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	<18	11,784 (15)	
51-100 19,984 (25) >100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	18-30	19,340 (24)	
>100 5,786 (7) Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	31-50	22,936 (29)	
Retired, n (%) 27,893 (31) Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	51-100	19,984 (25)	
Shift worker, n (%) 3,927 (4) Smoking status, n (%) 6,104 (7) Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	>100	5,786 (7)	
Smoking status, n (%) 6,104 (7) Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Retired, n (%)	27,893 (31)	
Current 6,104 (7) Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Shift worker, n (%)	3,927 (4)	
Former 31,910 (36) Never 50,718 (57) Sedative medication, n (%) 781 (<1) Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)	Smoking status, n (%)		
Never 50,718 (57) Sedative medication, n (%) 781 (<1)	Current	6,104 (7)	
Sedative medication, n (%) $781 (<1)$ Antidepressant medication, n (%) $5,145 (6)$ Prevalent cancer, n (%) $11,638 (13)$, , , ,		
Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)	Never	50,718 (57)	
Antidepressant medication, n (%) 5,145 (6) Prevalent cancer, n (%) 11,638 (13)	Sedative medication, n (%)	` ´	
		5,145 (6)	
Prevalent CVD, n (%) 36,279 (41)	Prevalent cancer, n (%)	11,638 (13)	
	Prevalent CVD, n (%)	36,279 (41)	
Prevalent diabetes, n (%) 3,759 (4)		`	
Prevalent neurological disease, n (%) 10,793 (12)		* *	
Prevalent mental and behavioural disorder, n (%) 8,187 (9)	· · · · · · · · · · · · · · · · · · ·	8,187 (9)	
Average night time sleep duration (hours; actigraphy-derived) 6.57 (8.33)	Average night time sleep duration (hours; actigraphy-derived)	* *	
Average night time wake after sleep onset (hours; actigraphy-derived) 0.79 (0.27)			
Sleep duration SD, hours 1.13 (0.57)		• •	
Sleep onset time SD, hours 1.02 (0.85)	÷	The state of the s	
SRI, score units 60.1 (10.2)	•	• •	

Data are mean (SD), unless specified otherwise. *pounds. SRI = sleep regularity index; CVD = cardiovascular disease.




Figure 1. Adjusted hazard ratios for all-cause (A), CVD (B), and cancer (C) mortality.

P values from global (2 degree of freedom) test of spline term. Hazard ratios (HR) are relative to the median SRI (SRI = 60). HRs for all-cause mortality, CVD mortality, and cancer mortality were estimated using Cox proportional hazards models, adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the SRI were modeled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for departures from linearity.




Figure 2. Cumulative incidence of all-cause mortality across SRI.

Standardized cumulative incidence of all-cause mortality for SRI at 41 (5th percentile), 61 (median), and 75 (95th percentile). Estimates from a discrete-time hazards models including an interaction between SRI and time (aggregated into 3-month intervals and modeled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles) and primary model covariates. Confidence intervals were obtained by bootstrapping.




Figure 3. Adjusted hazard ratios for all-cause mortality for the SRI (A), sleep duration SD (B), and sleep onset SD (C) measures.

P values from global (2 degree of freedom) test of exposure spline term. Hazard ratios (HR) are relative to the median SRI (SRI = 60). HRs were estimated using Cox proportional hazards models, adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the sleep regularity metrics were modeled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for departures from linearity.

Appendix Table of Contents Appendix 1: Removal of low-quality accelerometer data Appendix 2: STROBE checklist Figure S1. Directed acyclic graph for identification of adjustment variables Figure S2. Time-varying HRs for 5th and 95th percentiles of SRI (relative to median) for all-cause mortality Figure S3. Time-varying HRs for 5th and 95th percentiles of SRI (relative to median) for cancer-mortality Figure S4. SRI and all-cause mortality in sensitivity analyses Figure S5. SRI and CVD-mortality in sensitivity analyses Figure S6. SRI and cancer-mortality in sensitivity analyses

Appendix 1: Methods. Removal of low-quality accelerometer data

Accelerometry data of low quality were removed using established UKB criteria;
incongruity of self-reported wear time and accelerometer wear time data (5%); insufficient wear time (< 72 hours; 5%); and poorly calibrated data (<1%). Lastly, data were removed for participants in which GGIR was unable to determine a sleep window (5%) and for participants providing less than two valid SRI measurements (i.e., 2 24-hour wear periods; <1%). In total, 88,975 (84%) participants provided valid sleep regularity index data and were included in the study.

Item No Recommendation Title and abstract (a) Indicate the study's design with a commonly used term in the title or the abstract (see title) (b) Provide in the abstract an informative and balanced summary of what was done and what was found (see pg 2) Introduction Background/rationale 2 Explain the scientific background and rationale for the investigation being Objectives 3 State specific objectives, including any prespecified hypotheses (pg 3) Methods 4 Present key elements of study design early in the paper (Pg 3) Study design 5 Describe the setting, locations, and relevant dates, including periods of Setting recruitment, exposure, follow-up, and data collection (Pg 3) **Participants** 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up (Pg 3-4) (b) For matched studies, give matching criteria and number of exposed and unexposed NA Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable (Pg 4) 8* For each variable of interest, give sources of data and details of methods of Data sources/ assessment (measurement). Describe comparability of assessment methods if measurement there is more than one group (Pg 3-4) Describe any efforts to address potential sources of bias (pg 5) Bias 10 Study size Explain how the study size was arrived at (pg 3 and appendix) Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why (pg 5) Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (pg 4-5, Figure S1) (b) Describe any methods used to examine subgroups and interactions NA (c) Explain how missing data were addressed (pg 4-5) (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses (pg 5) Results 13* **Participants** (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (Pg 3) (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram Not considered necessary but can be created upon request Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Table 1 (b) Indicate number of participants with missing data for each variable of interest Missing data were infrequent, as described in methods (c) Summarise follow-up time (eg, average and total amount) (pg 5) Outcome data 15* Report numbers of outcome events or summary measures over time (pg 5) 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted Main results estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Figures and Appendix figures (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Figure 2

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (pg 6)	
Discussion			
Key results	18	Summarise key results with reference to study objectives (pg 7)	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias (pg 8)	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence (pg 8)	
Generalisability	21	Discuss the generalisability (external validity) of the study results (pg 7-8)	
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based (pg 8)	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.




Figure S1. Directed acyclic graph for identification of adjustment variables. The green node indicates the exposure variable (*SRI*), and the blue node (*Mortality*) is the outcome variable. Pale grey nodes indicate unobserved variables; white nodes indicate a variable which has been conditioned on (by regression adjustment or restriction). Paths in red are biasing paths. Arrows indicate the direction of causal effect between two nodes. *P* is an unobserved variable representing unmeasured causes of sleep habits (e.g., genetics). *U* is an unobserved variable representing unmeasured causes of disease and cardiovascular dysfunction (e.g., genetics, biological ageing). *Z* is an unobserved variable representing unmeasured causes of health behaviours (e.g., personality factors, genetics). Green paths from *SRI* to *Prevalent disease*, *BP medication*, *Systolic BP, BMI*, *and Physical activity* and from these nodes to *Mortality* represent potential mediation of an SRI effect. Conversely, red paths indicate potential sources of confounding (e.g., a backdoor path from *Mortality* to *Prevalent disease* to *SRI* via *U*). Given the current evidence base, we are unable to determine whether and to what extent variables such as *Prevalent disease* act as mediators or confounders (via *U*) of the SRI-mortality association. AP = anti-psychotic; AD = antidepressant; BMI = body mass index; BP = blood pressure; CVD = cardiovascular disease; Deprivation = the Townsend deprivation index; SRI = sleep regularity index; WASO = wake after sleep onset.




Figure S2. Time-varying HRs for 5th and 95th percentiles of SRI (relative to median) for all-cause mortality. A: Hazard ratios for 5th percentile vs median SRI; **B:** Hazard ratios for 95th percentile vs median SRI. Discrete time hazards model including time (aggregated into 3-month intervals and modelled with a restricted cubic spline with knots at the 5th, 35th, 65th, and 95th percentiles), SRI, and an SRI by time interaction. Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the SRI were modelled with restricted cubic splines (knots at 10th, 50th, and 90th percentiles) to allow for departures from linearity. There was strong evidence of an interaction between time and SRI (*p* [interaction] < 0.001).




Figure S3. Time-varying HRs for 5^{th} and 95^{th} percentiles of SRI (relative to median) for cancer-mortality. A: Hazard ratios for 5^{th} percentile vs median SRI; B: Hazard ratios for 95^{th} percentile vs median SRI. Discrete time hazards model including time (aggregated into 3-month intervals and modelled with a restricted cubic spline with knots at the 5^{th} , 35^{th} , 65^{th} , and 95^{th} percentiles), SRI, and an SRI by time interaction. Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category). All continuous confounders and the SRI were modelled with restricted cubic splines (knots at 10^{th} , 50^{th} , and 90^{th} percentiles) to allow for departures from linearity. There was strong evidence of an interaction between time and SRI (p [interaction] < 0.001).




Figure S4. SRI and all-cause mortality in sensitivity analyses. *P* values from global (2 degree of freedom) test of spline term. Hazard ratios are relative to the median SRI (SRI = 60).

Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), average sleep time, and average wake after sleep onset time. **M2 results:** HRs, relative to the median SRI, were 1.42 (95% CI: 1.31, 1.55) and 0.90 (95% CI: 0.80, 1.00) for SRI at the 5th and 95th percentiles, respectively.

Model 3 (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and cardiovascular illness. **M3 Results:** HRs, relative to the median SRI, were 1.46 (95% CI: 1.35, 1.58) and 0.93 (95% CI: 0.83, 1.03) for the 5th and 95th percentiles of SRI, respectively.

Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous physical activity, systolic blood pressure, and blood pressure medication. **M4 results:** HRs, relative to the median SRI, were 1.20 (95% CI: 1.11, 1.31) and 1.00 (95% CI: 0.90, 1.12) for the 5th and 95th percentiles, respectively.




Figure S5. SRI and CVD-mortality in sensitivity analyses. *P* values from global (2 degree of freedom) test of spline term. Hazard ratios are relative to the median SRI (SRI = 60).

 Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), average sleep time, and average wake after sleep onset time. **M2 results:** HRs were 1.66 (95% CI: 1.40, 1.96) and 0.95 (95% CI: 0.73, 1.22) for the 5th and 95th percentile vs. the median SRI, respectively.

Model (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and cardiovascular illness. **M3 results:** HRs were 1.73 (95% CI: 1.47, 2.02) and 0.99 (95% CI: 0.77, 1.26) for the 5th and 95th percentiles, respectively.

Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous physical activity, systolic blood pressure, and blood pressure medication. **M4 results:** HRs were somewhat attenuated: 1.43 (95% CI: 1.21, 1.69) and 1.09 (95% CI: 0.85, 1.40), for the 5th and 95th percentiles, respectively.




Figure S6. SRI and cancer-mortality in sensitivity analyses. *P* values from global (2 degree of freedom) test of spline term. Hazard ratios are relative to the median SRI (SRI = 60).

 Model 2 (M2) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), average sleep time, and average wake after sleep onset time. **M2 results:** HRs were 1.35 (95% CI: 1.20, 1.52) and 0.88 (95% CI: 0.76, 1.02) for the 5th and 95th percentile vs. the median SRI, respectively.

Model 3 (M3) adjustments: Adjusted for age, Townsend deprivation index, sex, antidepressant, antipsychotic, and sedative medication, ethnicity, household income, education, smoking status (former, current, never), smoking pack years, shift work, retirement status, and sick or disabled (self-reported employment category), and prevalent diabetes, cancer, mental and behavioural disorder, neurological illness, and cardiovascular illness. **M3 results:** HRs were 1.33 (95% CI: 1.19, 1.49) and 0.90 (95% CI: 0.78, 1.04) for the 5th and 95th percentiles, respectively.

Model 4 (M4) adjustments: Model 3 with additional adjustment for BMI, moderate and vigorous physical activity, systolic blood pressure, and blood pressure medication. **M4 results:** HRs were 1.15 (95% CI: 1.02, 1.30) and 0.97 (95% CI: 0.84, 1.12) for the 5th and 95th percentiles, respectively.